Application of neoadjuvant chemotherapy in treatment of cervical cancer 新輔助化療在宮頸癌中的應用
Neoadjuvant treatment for esophageal 食管癌的新輔助治療
Objective : to evaluate the status quo of the application of neoadjuvant chemotherapy 目的:對新輔助化療方案的臨床應用現(xiàn)狀進行評價。
Neoadjuvant chemotherapy with pirarubicin taxol regiment for the treatment of locally advanced breast cancer 方案三種化療方法治療非小細胞肺癌的療效觀察
To investigate , the researchers studied stage ii and ii breast cancer patients who were receiving neoadjuvant chemotherapy 研究人員對接受新輔助化療的ii期乳腺癌患者進行了研究。
The most notable notion is to administer neoadjuvant chemotherapy to reduce the size of the primary tumor before surgery 其中最令人關注的主張是在手術前以新輔助化療縮小原發(fā)性腫瘤的大小。
The expression of bcl - 2 and survivin protein and its relationship with therapeutic response of neoadjuvant chemotherapy in patients with breast cancer 2和生存素的表達及其與化療反應的相關性
For patients with pathologic complete response , neoadjuvant therapy may give additional benefit in prolonging overall survival 對于病理完全緩解的患者,新輔助治療可以帶來延長總體生存時間的益處。
However , concern has arisen regarding the potential for vascular complications due to high - dose neoadjuvant therapy before transplantation 但是,人們擔心移植前的高劑量新輔助治療有可能引發(fā)血管并發(fā)癥。
Conclusion : : the multimodality treatment of stage iii and iva thymomas by means of neoadjuvant chemotherapy provides good long - term outcomes in both stages of the disease :用新輔助化療的方法治療iii期和iva期胸腺瘤,為這兩期患者的治療提供了良好的長期的預后。